Affiliation:
1. CBQF—Centro de Biotecnologia e Química Fina, Laboratório Associado, Escola Superior de Biotecnologia, Universidade Católica Portuguesa, Rua Diogo Botelho 1327, 4169-005 Porto, Portugal
2. Amyris Bio Products Portugal Unipessoal Lda, 4169-005 Porto, Portugal
Abstract
Sugarcane, a globally cultivated crop constituting nearly 80% of total sugar production, yields residues from harvesting and sugar production known for their renewable bioactive compounds with health-promoting properties. Despite previous studies, the intricate interplay of extracts from diverse sugarcane byproducts and their biological attributes remains underexplored. This study focused on extracting the lipid fraction from a blend of selected sugarcane byproducts (straw, bagasse, and filter cake) using ethanol. The resulting extract underwent comprehensive characterization, including physicochemical analysis (FT-IR, DSC, particle size distribution, and color) and chemical composition assessment (GC-MS). The biological properties were evaluated through antihypertensive (ACE), anticholesterolemic (HMG-CoA reductase), and antidiabetic (alpha-glucosidase and Dipeptidyl Peptidase-IV) assays, alongside in vitro biocompatibility assessments in Caco-2 and Hep G2 cells. The phytochemicals identified, such as β-sitosterol and 1-octacosanol, likely contribute to the extract’s antidiabetic, anticholesterolemic, and antihypertensive potential, given their association with various beneficial bioactivities. The extract exhibited substantial antidiabetic effects, inhibiting α-glucosidase (5–60%) and DPP-IV activity (25–100%), anticholesterolemic potential with HMG-CoA reductase inhibition (11.4–63.2%), and antihypertensive properties through ACE inhibition (24.0–27.3%). These findings lay the groundwork for incorporating these ingredients into the development of food supplements or nutraceuticals, offering potential for preventing and managing metabolic syndrome-associated conditions.
Funder
Amyris Bio Products Portugal, Unipessoal Lda
Escola Superior de Biotecnologia
Reference57 articles.
1. Shenoy, A., Buttar, H.S., Dicholkar, P., Kaur, G., and Chintamaneni, M. (2022). Functional Foods and Nutraceuticals Metabolic and Non-Communicable Diseases, Elsevier.
2. Hayden, M.R. (2023). Overview and New Insights into the Metabolic Syndrome: Risk Factors and Emerging Variables in the Development of Type 2 Diabetes and Cerebrocardiovascular Disease. Medicina, 59.
3. Novel Insights into the Pathogenesis and Management of the Metabolic Syndrome;Wang;Pediatr. Gastroenterol. Hepatol. Nutr.,2020
4. Applying the WHO Global Targets for Diabetes Mellitus;Cheng;Nat. Rev. Endocrinol.,2023
5. Global and Regional Diabetes Prevalence Estimates for 2019 and Projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9th Edition;Saeedi;Diabetes Res. Clin. Pract.,2019